Regulatory Affairs Consultancy for Medical Devices & IVD

A medical device regulatory affairs consultancy manages the strategy, documentation, and submissions that bring a device or IVD to market legally and keep it there. That spans classification, technical documentation, EU MDR or IVDR and FDA submissions, Notified Body liaison, and post-market obligations following approval.

Why the regulatory burden keeps growing

EU MDR and IVDR did not just add paperwork. Both regulations pushed a meaningful share of legacy devices into higher-risk categories: EU MDR classification rules reclassified categories such as certain reusable surgical instruments and software as a medical device, while IVDR's risk-based classification system moved roughly 80% of IVDs from self-certification into Notified Body oversight, up from around 20% under the old directive.

A device that previously cleared under a self-declaration may now require a full technical file, a clinical or performance evaluation, and an active post-market surveillance program. For a QA/RA team already stretched thin, that shift lands hardest on two fronts: knowing what a reviewer will actually accept as sufficient evidence, and finding the hours to produce it without stalling next year's product pipeline. New development is often the casualty — legacy compliance eats the budget and the calendar first.

Qserve's approach: practical, not just compliant

Compliance on paper is not the same as compliance that a Notified Body or FDA reviewer accepts without several rounds of follow-up questions. Qserve's regulatory affairs consultants combine deep regulatory knowledge with hands-on industry and Notified Body experience, so the guidance reflects what a review actually tests for, not just what the regulation states in the abstract.

That translates into fewer review cycles and faster market access. Where a generalist consultancy tells you what the rule says, we tell you what "good enough" looks like for your specific device, and where your file falls short of it before a reviewer finds the gap.

When you need regulatory affairs support

• Adapting a legacy device or IVD to EU MDR or IVDR, including reclassification and technical file upgrades
• Preparing an FDA 510(k), De Novo, or PMA submission for the US market
• Registering a product across several international markets at the same time
• Losing a QA/RA manager or specialist and needing qualified interim coverage without a hiring gap
• Running regulatory due diligence ahead of a merger, acquisition, or investment round
• Building a first regulatory strategy for a start-up bringing its first device to market

How regulatory affairs differs from QA and clinical support at Qserve

Regulatory affairs, quality assurance, and clinical investigations are three distinct disciplines that sit under one roof at Qserve, and most manufacturers need more than one at a time.

Regulatory affairs owns the submission itself: classification, technical documentation, and the dossier that a Notified Body or FDA reviews.

Quality assurance covers the management system behind that dossier. The ISO 13485 processes, CAPA, and audit readiness that keep the file defensible after approval.

Clinical investigations generate the clinical or performance evidence that a strong dossier depends on, particularly for higher-class devices.

Most engagements touch at least two of the three. A regulatory strategy is only as strong as the QMS and clinical evidence supporting it, which is why a Qserve project usually pulls in specialists from more than one team rather than treating them as separate workstreams.

EU MDR/IVDR and FDA 510(k): one team, two regulatory systems

Most medical device and IVD manufacturers selling in both the EU and US need parallel regulatory pathways: EU MDR or IVDR conformity assessment through a Notified Body, and an FDA 510(k) premarket notification or PMA submission through the FDA. Qserve's regulatory affairs consultants run both processes together, so evidence generated for one submission is reused rather than duplicated for the other.

The two systems ask different questions of the same technical file: a Notified Body assesses evidence against MDR/IVDR general safety and performance requirements, while FDA assesses substantial equivalence to a predicate device or, for higher-risk devices, a full safety and effectiveness case under a PMA. Planning both pathways from the same technical documentation avoids rebuilding the file twice and keeps one consistent regulatory strategy across markets.